Rivaroxaban for Slow Coronary Flow After PCI in STEMI

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
ST Elevation Myocardial InfarctionNo-Reflow Phenomenon
Interventions
DRUG

Dual Antiplatelet (DAPT) Therapy

aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days

DRUG

Rivaroxaban

Rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily plus clopidogrel 75 mg daily for 30 days

All Listed Sponsors
collaborator

Affiliated Hospital of Jiaxing University

OTHER

collaborator

The Second Affiliated Hospital of Jiaxing University

OTHER

collaborator

Wenzhou People's Hospital

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER